United Neuroscience (UNS), a clinical-stage biotech company pioneering a new class of medicine to treat and prevent brain disorders, today announced positive top-line results from its Phase 2a clinical study of UB-311, a novel synthetic peptide vaccine targeting beta amyloid (Aβ) in the treatment of Alzheimer’s disease. The top-line Phase 2a data met the primary aims of safety and immunogenicity with a 96% response rate. All secondary endpoints—including Amyloid PET burden, CDR-SB, ADCS-ADL, ADAS-Cog and MMSE—pointed directionally in favor of UB-311, though not statistically significant with the study sample size.
“The positive results show that we can safely raise and maintain anti-Aβ antibody titers in a predictable and sustained manner,” said Peter Powchik, Executive Vice President of Research and Development at UNS. “High response rates, reproducibility of response and generation of antibodies directed to relevant toxic protein species are key elements of an effective therapeutic vaccine for neurodegenerative conditions. The UNS platform is proving that it can deliver on these requirements.”
Chief Executive Officer Mei Hu added, “These early results suggest a clinical response and support the continued and rapid development of UB-311. The intent of this Phase 2a study was to acquire directional information on the safety, tolerability and therapeutic potential of UB-311 in patients with Alzheimer’s disease. UNS is committed to transforming the lives of patients and families affected by Alzheimer’s by tackling the seemingly impossible, and bringing an end to Alzheimer’s through a safe, effective and accessible active immunotherapy that can treat and ultimately prevent the disease.”
The Phase 2a double blinded, placebo-controlled study evaluated the safety and immunogenicity of prolonged dosing with two different dosing regimens of UB-311. Subjects from the completed Phase 2a study will roll over into a long-term extension study and will be offered continued treatment with UB-311. Additional results, including future analysis of secondary endpoints and other data, are expected to be presented at upcoming medical meetings, such as the 14th International Conference on Alzheimer’s and Parkinson’s Diseases, and published in peer reviewed medical journals.